Bellevue Group AG Increases Stake in NewAmsterdam Pharma (NASDAQ:NAMS)

Bellevue Group AG lifted its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 224.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,000 shares of the company's stock after purchasing an additional 17,300 shares during the quarter. Bellevue Group AG's holdings in NewAmsterdam Pharma were worth $642,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. grew its stake in shares of NewAmsterdam Pharma by 176.9% during the third quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock valued at $371,000 after buying an additional 14,280 shares during the last quarter. Legal & General Group Plc increased its position in shares of NewAmsterdam Pharma by 24.8% in the fourth quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock valued at $590,000 after acquiring an additional 4,556 shares during the period. American Century Companies Inc. bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at about $8,907,000. Geode Capital Management LLC boosted its holdings in shares of NewAmsterdam Pharma by 1.6% during the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock worth $1,433,000 after purchasing an additional 1,399 shares during the period. Finally, Swiss National Bank raised its position in NewAmsterdam Pharma by 105.1% during the 4th quarter. Swiss National Bank now owns 72,000 shares of the company's stock valued at $1,850,000 after purchasing an additional 36,900 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Up 1.8 %

NASDAQ:NAMS traded up $0.35 during mid-day trading on Thursday, hitting $19.27. 1,326,932 shares of the stock traded hands, compared to its average volume of 616,483. The firm's 50 day moving average is $19.60 and its two-hundred day moving average is $21.23. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $27.29. The stock has a market capitalization of $2.12 billion, a price-to-earnings ratio of -7.41 and a beta of 0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04). As a group, research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Activity

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. This represents a 90.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director James N. Topper purchased 4,005 shares of the stock in a transaction on Tuesday, March 4th. The stock was acquired at an average cost of $21.02 per share, with a total value of $84,185.10. Following the acquisition, the director now owns 3,012,434 shares of the company's stock, valued at approximately $63,321,362.68. This represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. Insiders own 19.50% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on NAMS. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research report on Monday, March 3rd. Needham & Company LLC dropped their price objective on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a report on Thursday. HC Wainwright reaffirmed a "buy" rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Scotiabank boosted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $43.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.